For patients with obesity and prediabetes, three years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according to a study ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in ...

New data shows that government-funded health insurance plans in the United States provide the majority of coverage for ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...

Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

Doctors say they have not seen anything like this since the emergence of statins to lower cholesterol. But do we know enough ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...